Table 1

Summary of the characteristics of the non-comparative studies (n = 26)

Characteristics

Mean (range)

Frequency studies/patients (%)


Sample size

59 (range:10–206)

Age (years)

67.5 ± 2.9 (47–90)

Follow-up (months) [n]

16 ± 15 (1–63)

Continent

Europe

13 (50%)

America

6 (23%)

Asia

3 (11.5%)

Australia

3 (11.5%)

Africa

1 (4%)

Studies in languages other than English

3 (11.5%)

Type of study

Design

Prospective

24 (92%)

Retrospective

1 (4%)

Unknown

1 (4%)

Single-center

17 (65.4%)

Multicenter

9 (34.6%)

Type of anesthesia

Local

3 (13%)

Local+sedation

10 (43.5%)

Spinal

3 (13%)

General

2 (8.7%)

General/local+sedation

5 (22%)

    Variables assessed

Symptoms

25 (96.2%)

Quality of life score

22 (84.6%)

Qmax (mL/s)

25 (96.2%)

PVR (mL)

17 (65.4%)

Sexual function

12 (46.2%)

Pressure-flow studies

7 (26.9%)

Prostatic size

13 (50%)

Re-treatment

17 (65.4%)

Adverse effects

22 (84.6%)

Duration of procedure

15 (57.7%)

Hospital stay

11 (42.3%)

Quality assessment

Consecutive or representative sample

Yes: 21 No: 3 Not reported:2

Presence of cointerventions

Yes: 19 No: 1 Not reported:6

Evaluation blind or independent

Yes: 0 No: 26 Not reported:0

Losses to follow-up ≥ 20%

Yes:11 No:9 Not reported:6


Bouza et al. BMC Urology 2006 6:14   doi:10.1186/1471-2490-6-14

Open Data